Advanced Search
DAI Yi, LI Jing-dong, ZHAO Guo-gang, LIU Hui, LONG Juan, ZOU Lin. Correlative Expressions of β-arrestin1 and MMP-9 in Hepatocelluar Carcinoma Tissues[J]. Cancer Research on Prevention and Treatment, 2011, 38(02): 170-173. DOI: 10.3971/j.issn.1000-8578.2011.02.014
Citation: DAI Yi, LI Jing-dong, ZHAO Guo-gang, LIU Hui, LONG Juan, ZOU Lin. Correlative Expressions of β-arrestin1 and MMP-9 in Hepatocelluar Carcinoma Tissues[J]. Cancer Research on Prevention and Treatment, 2011, 38(02): 170-173. DOI: 10.3971/j.issn.1000-8578.2011.02.014

Correlative Expressions of β-arrestin1 and MMP-9 in Hepatocelluar Carcinoma Tissues

More Information
  • Received Date: January 21, 2010
  • Revised Date: May 26, 2010
  • objectiveTo investigate the expressions and significance of β-arrestin1 and matrix metalloproteinase-9 (MMP-9) in hepatocecullar carcinoma patients. Methods The tumor tissues and tumor-adjacent tissues were simultaneously collected from 35 patients in operation with diagnosed hepatocellular carcinoma,which included 23 cases of phase Ⅱ and 12 cases of phase Ⅲ. And 15 non-tumor tissues were enrolled in this study as the normal control (NL group). Then the mRNA and protein expression of β-arrestin1 were detected by using quantitative real-time RT-PCR and Western blot respectively. The protein concentration of MMP-9 of these tissues was measured by ELISA. Results All the mRNA and protein expressions of β-arrestin1 were measured in the samples of normal liver tissues,HCC tumor and its adjacent tissues. Compared with the normal group and tumor-adjacent group,the mRNA and protein expressions of β-arrestin1 in HCC group of different clinical phases increased significantly (P<0.05). The expression level was increased with the advanced phases. The concentration of MMP-9,increased in HCC tumor tissues,was positively correlated with β-arrestin1 expreesion(P<0.05) . ConclusionThe expressions of β-arrestin1 significantly up-regulated in HCC tumor tissues,which was positively related to the concentration of MMP-9,indicating that they might be related to progression of hepartocecullar carcinoma and to be the diagnosis and therapy target of HCC.
  • Related Articles

    [1]YAO Weirong, WAN Huiping, YU Yanmin, LUO Lifang, ZHANG Xiquan, TANG Zhimou. Effects of Stability Plasma Concentration of 5-Fu and Docetaxel on Adverse Events and Short Term Effect after 5-Fu and Docetaxel Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 53-56. DOI: 10.3971/j.issn.1000-8578.2014.01.012
    [2]Yang Liuzhong, Cui Yanhui, Kou Weizheng, Kou Xiaoge, Miao Zhanhui, Niu Hongrui. Clinical Observation on Thalidomide Accompanied Docetaxel in Chemotherapy Patients with Advanced Non-small Cell Lung Cancer As Second-line Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(03): 324-328. DOI: 10.3971/j.issn.1000-8578.2012.03.020
    [3]Liao Jiahua, Lin Huanxin, Sun Jian, Sun Rui, Guo Ling. Chrono-chemotherapy of Docetaxel in Nude Mice Bearing Human Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(01): 18-22. DOI: 10.3971/j.issn.1000-8578.2012.01.005
    [4]CAI Yong-guang, LI Ming, XIE Xin. Clinical Observation of Docetaxel or Gemcitabine Combine with Cisplatin in Treatment of Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(11): 1308-1311. DOI: 10.3971/j.issn.1000-8578.2010.11.027
    [5]CHEN Kun, LIN Qiang, ZHAO Yan- nan, BI Yan-hua, WANG Na, LIU Yue-e. Comparison of Gemcitabine and Paclitaxel Combined with Fractionation-dose Cisplatin in Treatment of Untreated Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 709-711. DOI: 10.3971/j.issn.1000-8578.2010.06.028
    [6]HAN Xiao, WANG Zhe-hai, GUO Jun, LIU Lin, LIU Li-yan. Clinical Observation of Docetaxel Combined with Vinorelbine as Second Line Treatment for Patients with Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 705-708. DOI: 10.3971/j.issn.1000-8578.2010.06.027
    [7]FU Xiao-min, WANG Jing, ZHANG Hui, BAO Ai-hua. Clinical Research for Docetaxel Plus Cisplatin in Untreated Adwanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 205-208. DOI: 10.3971/j.issn.1000-8578.2010.02.022
    [8]ZHAN Shan-shan, WANG Zhi-gang, FU Mu-chang. Docetaxel Combined with Intraperitoneal Fluorouracil Chemotherapy in Treatment of Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(02): 153-155.
    [9]HUANG Cheng-suo, WANG Zhe-hai, CHEN zhen. Clinical Study of Docetaxel Combined with Cisplatin and Fluorouracil in Treatment of Advanced Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(06): 436-438. DOI: 10.3971/j.issn.1000-8578.2322
    [10]LIU Zhi-hui, ZHOU Wen-xian, LI Yong-qiang, HU Xiao-hua. Gemcitabine Plus Carboplatin as Second-line Chemotherapy in Patients with Advanced Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(12): 962-964. DOI: 10.3971/j.issn.1000-8578.1703

Catalog

    Article views (2271) PDF downloads (586) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return